Primary Job Title Board of Directors Primary Organization Kuur Therapeutics
Gender Male
LinkedIn View on LinkedIn
Nigel was a member of the senior management team at Cambridge Antibody Technology and brings over 20 years experience in the biotech sector to Cell Medica.
At CAT, he was responsible for strategic alliances and led negotiations of significant transactions with other pharmaceutical and biotech companies including the early discussions with Astra
Zeneca, which acquired CAT in 2006.
He also chaired CAT’s Product Steering Committee, responsible for product management strategy and pipeline. (BSc Biochemistry PhD, Imperial College London).
